Patents by Inventor Pingyan WANG
Pingyan WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11827713Abstract: Provided is a chimeric antibody immune cell engager comprising a target cell binding domain that specifically binds to an antigen on a target cell, and an immune effector cell binding domain comprising an antigen-binding fragment that specifically binds to an antigen on an immune effector cell. Also provided are pharmaceutical compositions, kits and methods of treatment.Type: GrantFiled: June 27, 2018Date of Patent: November 28, 2023Assignee: Nanjing Legend Biotech Co., Ltd.Inventors: Xiaohu Fan, Qiuchuan Zhuang, Lei Yang, Pingyan Wang, Qingyan Li
-
Publication number: 20230085615Abstract: A modified T cell comprising a functional exogenous receptor is provided. The functional exogenous receptor comprises: (a) an extracellular ligand binding domain, (b) a transmembrane domain, and (c) an intracellular signaling domain (ISD) comprising a chimeric signaling domain (CMSD), wherein the CMSD comprises a plurality of Immune-receptor Tyrosine-based Activation Motifs (ITAMs) optionally connected by one or more linkers. Further provided are vectors, methods of producing, pharmaceutical compositions, kits, and methods of treatment thereof.Type: ApplicationFiled: August 28, 2020Publication date: March 16, 2023Applicant: Nanjing Legend Biotech Co., Ltd.Inventors: Xiaohu FAN, Yuncheng ZHAO, Bing WANG, Dawei YU, Xin HUANG, Pingyan WANG, Qiuchuan ZHUANG
-
Patent number: 11564945Abstract: Disclosed herein is a novel chimeric antigen receptor and use thereof. The novel chimeric antigen receptor consists of a signal peptide, an antigen binding domain, a transmembrane region, and an intracellular signal domain, and comprises a 4-1BB signal peptide and/or a 4-1BB molecular transmembrane region. Nucleic acid sequences of various chimeric antigen receptors are separated and purified and provided is a chimeric antigen receptor and a CAR-T cell which are specific for a CD19 malignant tumor antigen. In the malignant tumor killing test of hematological cell lines, the ability of immune cells to target and recognize tumor cells is significantly enhanced, and the killing activity against tumor cells is also enhanced.Type: GrantFiled: December 29, 2017Date of Patent: January 31, 2023Assignee: Nanjing Legend Biotech Co., Ltd.Inventors: Xiaohu Fan, Qiuchuan Zhuang, Pingyan Wang, Lei Yang, Xiujun Zheng, Jiaying Hao, Shaobo Liu
-
Patent number: 11535677Abstract: Provided herein are single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) having the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: GrantFiled: August 10, 2017Date of Patent: December 27, 2022Assignee: LEGEND BIOTECH USA INC.Inventors: Xiaohu Fan, Qiuchuan Zhuang, Pingyan Wang, Lin Wang, Lei Yang, Jiaying Hao, Dan Zhao, Xian He
-
Publication number: 20220313738Abstract: A modified T cell comprises: i) an exogenous Negative Regulatory Factor (Nef) protein; and ii) a functional exogenous receptor comprising: (a) an extracellular ligand binding domain, (b) a transmembrane domain, and (c) an intracellular signaling domain (ISD) comprising a chimeric signaling domain (CMSD), wherein the CMSD comprises one or a plurality of Immune-receptor Tyrosine-based Activation Motifs (ITAMs), wherein the plurality of CMSD ITAMs are optionally connected by one or more linkers. Provided are also Nef proteins (e.g., non-naturally occurring Nef), and modified T cells comprising such Nef proteins. Provided are methods of making and uses thereof.Type: ApplicationFiled: August 28, 2020Publication date: October 6, 2022Applicant: Nanjing Legend Biotech Co., Ltd.Inventors: Xiaohu FAN, Yuncheng ZHAO, Bing WANG, Dawei YU, Xin HUANG, Pingyan WANG, Qiuchuan ZHUANG
-
Publication number: 20220289814Abstract: A modified T cell comprising a functional exogenous receptor is provided. The functional exogenous receptor comprises: (a) an extracellular ligand binding domain, (b) a transmembrane domain, and (c) an intracellular signaling domain (ISD) comprising a chimeric signaling domain (CMSD), wherein the CMSD comprises a plurality of Immune-receptor Tyrosine-based Activation Motifs (ITAMs) optionally connected by one or more linkers. Further provided are vectors, methods of producing, pharmaceutical compositions, kits, and methods of treatment thereof.Type: ApplicationFiled: August 28, 2020Publication date: September 15, 2022Applicant: Nanjing Legend Bioteh Co., Ltd.Inventors: Xiaohu FAN, Yuncheng ZHAO, Bing WANG, Dawei YU, Xin HUANG, Pingyan WANG, Qiuchuan ZHUANG
-
Patent number: 11401317Abstract: The present invention relates to a human CD123-targeting chimeric receptor ligand, comprising an IL-3 molecule-based CD123 binding domain, a transmembrane region, and an intracellular signaling domain. The present invention provides a T cell modified by the human CD123-targeting chimeric receptor ligand and capable of specifically binding with CD123 on tumor cell surfaces, thereby having specific cytotoxicity on tumor cells. The present invention further relates to an application of the human CD123-targeting chimeric receptor ligand and an immune effector cell thereof in preparing an anti-tumor immunotherapy drug.Type: GrantFiled: August 31, 2017Date of Patent: August 2, 2022Assignee: Nanjing Legend Biotech Co., Ltd.Inventors: Qiuchuan Zhuang, Xiaohu Fan, Lei Yang, Pingyan Wang
-
Publication number: 20220177524Abstract: Provided are a method of producing a modified T cell comprising introducing into a precursor T cell a first nucleic acid encoding a Nef protein, wherein the Nef protein upon expression results in down-modulation of the endogenous T cell receptor (TCR) in the modified T cell, wherein the modified T cell furthermore expresses a functional exogenous receptor, such as an engineered TCR (e.g., chimeric TCR), T cell antigen coupler (TAC), TAC-like chimeric receptor, or a chimeric antigen receptor (CAR), the modified cell obtained by the method and the pharmaceutical composition comprising the modified T cell. Also provided is a non-naturally occurring Nef protein comprising one or more mutations.Type: ApplicationFiled: July 26, 2019Publication date: June 9, 2022Inventors: Xiaohu FAN, Yuncheng ZHAO, Dawei YU, Wujinan ZHI, Chenchen WANG, Qiuchuan ZHUANG, Pingyan WANG, Xuanxuan GUO
-
Publication number: 20220127371Abstract: The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: ApplicationFiled: November 3, 2021Publication date: April 28, 2022Applicant: Legend Biotech USA Inc.Inventors: Xiaohu FAN, Qiuchuan ZHUANG, Pingyan WANG, Lin WANG, Lei YANG, Jiaying HAO, Dan ZHAO, Xian HE
-
Patent number: 11186647Abstract: The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: GrantFiled: February 4, 2021Date of Patent: November 30, 2021Assignee: LEGEND BIOTECH USA INC.Inventors: Xiaohu Fan, Qiuchuan Zhuang, Pingyan Wang, Lin Wang, Lei Yang, Jiaying Hao
-
Publication number: 20210363218Abstract: Provided are chimeric receptors targeting NKG2D, and multispecific chimeric receptors comprising an NKG2D domain and a second antigen binding domain such as an IL-3 domain. Also provided are dual chimeric receptor systems comprising a first chimeric receptor comprising an NKG2D domain, and a second chimeric receptor comprising a second antigen binding domain such as an IL-3 domain. Further provided are engineered immune effector cells (such as T cells), pharmaceutical compositions, kits and methods of treating cancer.Type: ApplicationFiled: December 28, 2018Publication date: November 25, 2021Inventors: Xiaohu FAN, Jun WANG, Pingyan WANG, Qiuchuan ZHUANG, Lian MA
-
Publication number: 20210261675Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: ApplicationFiled: February 1, 2021Publication date: August 26, 2021Applicant: Legend Biotech USA Inc.Inventors: Xiaohu FAN, Chuan-Chu CHOU, Qiuchuan ZHUANG, Pingyan WANG, Lin WANG, Lei YANG, Jiaying HAO
-
Publication number: 20210163615Abstract: The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: ApplicationFiled: February 4, 2021Publication date: June 3, 2021Applicant: Legend Biotech USA Inc.Inventors: Xiaohu FAN, Qiuchuan ZHUANG, Pingyan WANG, Lin WANG, Lei YANG, Jiaying HAO, Dan ZHAO, Xian HE
-
Patent number: 10934363Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: GrantFiled: August 10, 2016Date of Patent: March 2, 2021Assignee: Legend Biotech USA Inc.Inventors: Xiaohu Fan, Chuan-Chu Chou, Qiuchuan Zhuang, Pingyan Wang, Lin Wang, Lei Yang, Jiaying Hao
-
Publication number: 20200123269Abstract: Provided is a chimeric antibody immune cell engager comprising a target cell binding domain that specifically binds to an antigen on a target cell, and an immune effector cell binding domain comprising an antigen-binding fragment that specifically binds to an antigen on an immune effector cell. Also provided are pharmaceutical compositions, kits and methods of treatment.Type: ApplicationFiled: June 27, 2018Publication date: April 23, 2020Inventors: Xiaohu FAN, Quichuan ZHUANG, Lei YANG, Pingyan WANG, Qingyan LI
-
Publication number: 20200078399Abstract: Provided herein are single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) having the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: ApplicationFiled: August 10, 2017Publication date: March 12, 2020Inventors: Xiaohu FAN, Qiuchuan ZHUANG, Pingyan WANG, Lin WANG, Lei YANG, Jiaying HAO, Dan ZHAO, Xian HE
-
Publication number: 20190321404Abstract: Disclosed herein is a novel chimeric antigen receptor and use thereof. The novel chimeric antigen receptor consists of a signal peptide, an antigen binding domain, a transmembrane region, and an intracellular signal domain, and comprises a 4-1BB signal peptide and/or a 4-1BB molecular transmembrane region. Nucleic acid sequences of various chimeric antigen receptors are separated and purified and provided is a chimeric antigen receptor and a CAR-T cell which are specific for a CD19 malignant tumor antigen. In the malignant tumor killing test of hematological cell lines, the ability of immune cells to target and recognize tumor cells is significantly enhanced, and the killing activity against tumor cells is also enhanced.Type: ApplicationFiled: December 29, 2017Publication date: October 24, 2019Applicants: Nanjing Legend Biotech Co., Ltd., Nanjing Legend Biotech Co., Ltd.Inventors: Xiaohu FAN, Qiuchuan ZHUANG, Pingyan WANG, Lei YANG, Xiujun ZHENG, Jiaying HAO, Shaobo LIU
-
Publication number: 20190225668Abstract: The present invention relates to a human CD123-targeting chimeric receptor ligand, comprising an IL-3 molecule-based CD123 binding domain, a transmembrane region, and an intracellular signaling domain. The present invention provides a T cell modified by the human CD123-targeting chimeric receptor ligand and capable of specifically binding with CD123 on tumor cell surfaces, thereby having specific cytotoxicity on tumor cells. The present invention further relates to an application of the human CD123-targeting chimeric receptor ligand and an immune effector cell thereof in preparing an anti-tumor immunotherapy drug.Type: ApplicationFiled: August 31, 2017Publication date: July 25, 2019Applicant: Nanjing Legend Biotech Co., Ltd.Inventors: Qiuchuan Zhuang, Xiaohu Fan, Lei Yang, Pingyan Wang
-
Publication number: 20190038671Abstract: The present invention provides a cell-based platform for controllable, regionalized, and cost-effective delivery of immunomodulator and other therapeutic proteins, which is widely applicable in cancer immunotherapy.Type: ApplicationFiled: January 26, 2017Publication date: February 7, 2019Inventors: Xiaohu FAN, Fangliang ZHANG, Qiuchuan ZHUANG, Pingyan WANG, Jie YU, Xian HE, Lin WANG, Jiaying HAO, Lei YANG
-
Publication number: 20180230225Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: ApplicationFiled: August 10, 2016Publication date: August 16, 2018Inventors: Xiaohu FAN, Chuan-Chu CHOU, Qiuchuan ZHUANG, Pingyan WANG, Lin WANG, Lei YANG, Jiaying HAO